Pharmacotherapy should be initiated first and continued for a minimum of 12 weeks before any psychotherapy is introduced

Because medication must first stabilize the neurobiological stress response before trauma-focused work can be tolerated. Starting psychotherapy concurrently with medication would overwhelm an already dysregulated nervous system and increase the risk of symptom exacerbation and treatment dropout. The sequential approach ensures that the patient achieves sufficient symptomatic improvement from medication to engage meaningfully in trauma processing. Guidelines uniformly recommend completing a full pharmacotherapy trial before considering referral for evidence-based psychotherapy. There is no requirement to complete a full pharmacotherapy trial before initiating trauma-focused psychotherapy, and concurrent initiation of both modalities is supported by current guidelines.

The evidence-based approach is to prioritize referral for a trauma-focused psychotherapy such as Cognitive Processing Therapy or Prolonged Exposure as the primary treatment

While initiating an SSRI such as sertraline or paroxetine as an adjunct to address symptom burden and functional impairment during the therapy course. Current guidelines identify trauma-focused psychotherapies as having the strongest evidence base for PTSD, while SSRIs are recommended when pharmacotherapy is indicated, and the two modalities can be initiated concurrently or sequentially based on patient readiness and symptom severity. Pharmacotherapy may enhance the patient's capacity to engage in psychotherapy by reducing hyperarousal and improving sleep, while psychotherapy addresses the underlying trauma-related cognitions and avoidance behaviors. This accurately reflects current evidence-based guidelines for PTSD treatment.

Benzodiazepines should be the initial pharmacological intervention paired with supportive counseling

Because the patient's hyperarousal symptoms require immediate anxiolytic relief before any trauma-focused work can begin. Benzodiazepines provide rapid reduction in hypervigilance, startle response, and insomnia, which are the most functionally impairing symptoms in this presentation. Once acute hyperarousal is controlled with benzodiazepine therapy, the patient can be transitioned to trauma-focused psychotherapy with better engagement and reduced dropout risk. This approach of pharmacological stabilization followed by psychotherapy is the standard combined treatment algorithm for combat-related PTSD. Benzodiazepines are specifically not recommended for the treatment of PTSD in current VA/DoD and APA guidelines.

The most effective plan is to initiate both a high-dose SSRI and an atypical antipsychotic simultaneously as the pharmacological foundation while deferring psychotherapy until the patient achieves at least a 50 percent reduction in PCL-5 scores from medication alone

Combined psychopharmacology with dual agents produces the most robust symptom reduction and creates the optimal neurobiological conditions for eventual trauma processing. Psychotherapy should only be introduced once pharmacotherapy has produced substantial improvement, as this indicates the patient's neural circuitry has been sufficiently modulated to benefit from psychological intervention. This stepped pharmacology-first model is the current gold standard for severe PTSD. There is no evidence supporting a mandatory dual-agent pharmacological approach as an initial treatment strategy for PTSD, nor is there a requirement to achieve a specific percentage of symptom reduction before initiating psychotherapy.